Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Literature DB >> 28465517

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian, R Mesa, F Passamonti, M F McMullin, V Ribrag, G Schiller, A M Vannucchi, D Zhou, D Reiser, J Zhong, R P Gale.

Abstract

Entities: Chemical Disease Species

Year: 2017 PMID： 28465517 PMCID： PMC7608297 DOI： 10.1038/leu.2017.2

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

Correction to: Leukemia advance online publication 18 November 2016; doi:10.1038/leu.2016.300 Following the online publication of this article, the authors noted that Dr McMullin was incorrectly excluded from the author list. The complete author names are given above. Dr McMullin’s affiliation is Department of Haematology, Queen’s University, Belfast, UK.

11 in total

Review 1. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors: Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2019-08 Impact factor: 3.952

Review 2. Management of Myelofibrosis-Related Cytopenias.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2018-06 Impact factor: 3.952

Review 3. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors: Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal: Leukemia Date: 2018-02-27 Impact factor: 11.528

Review 4. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.

Authors: Julian A Waksal; John Mascarenhas
Journal: Curr Hematol Malig Rep Date: 2022-08-19 Impact factor: 4.213

Review 5. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors: Andrew T Kuykendall; Rami S Komrokji
Journal: J Immunother Precis Oncol Date: 2021-06-22

6. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.

Authors: Onima Chowdhury; Jennifer O'Sullivan; Nikolaos Barkas; Guanlin Wang; Gemma Buck; Angela Hamblin; Ayalew Tefferi; Haifa K Al-Ali; Giovanni Barosi; Timothy Devos; Heinz Gisslinger; Qian Jiang; Jean-Jacques Kiladjian; Ruben Mesa; Francesco Passamonti; Vincent Ribrag; Gary Schiller; Alessandro M Vannucchi; Daobin Zhou; Mary Frances McMullin; Jianhua Zhong; Robert Peter Gale; Adam J Mead
Journal: Leukemia Date: 2020-08-07 Impact factor: 11.528

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Review 1. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Review 2. Management of Myelofibrosis-Related Cytopenias.

Review 3. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Review 4. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.

Review 5. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

6. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.

Review 7. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Review 8. Treatment of Myelofibrosis: Old and New Strategies.

Review 9. Standard care and investigational drugs in the treatment of myelofibrosis.

Review 10. Rethinking clinical trial endpoints in myelodysplastic syndromes.